论文部分内容阅读
疫苗时代育龄期妇女体内麻疹抗体多为麻疹疫苗所介导 ,所生婴儿母传抗体消失提前 ,未及初免月龄已成为易感者。针对北京市及其它一些大城市 <8月龄婴儿麻疹发病越来越突出的情况 ,为控制该人群发病 ,选取北京市户籍的 6月龄婴儿 119人进行麻疹减毒活疫苗 (MV)免疫效果及人体反应观察。结果显示 :6月龄婴儿中有 84%母传抗体已阴转 ,阳性者抗体水平也极低。接种MV后抗体阳性率达到 86 6 % ,免疫成功率为 80 7% ,几何平均滴度 (GMT)为 1∶5 2 8 45 ;接种后的发热率、皮疹率分别为 16 8%、2 5 2 %。提示实施 6月龄的MV初免程序是可行的。与本市 8月龄婴儿初免监测数据相比 ,6月龄婴儿的MV免疫成功率和GMT偏低 ,提示婴儿母传抗体的存在对MV的免疫成功率有一定的干扰作用外 ,与年龄相关的因素如低月龄婴儿免疫系统的发育程度可能是影响免疫效果的更为主要的因素。建议 :对 6月龄和 8月龄婴儿MV初免的成本效果进行研究 ,如果采取 6月龄初免 ,应考虑在满 1岁时复种 1剂MV ;加快研制免疫原性好并适用于低月龄婴儿的新型MV ;对与年龄有关的因素作更深入的探索。
Vaccine era of women of childbearing age more than measles-resistant body-mediated vaccination of infants and mothers born antibodies disappear in advance, not as early as the age-free has become a susceptible. In order to control the incidence of measles in infants <8 months of age in Beijing and other large cities, 119 immunized children aged 6 months from Beijing were enrolled in this study. And human reaction observed. The results showed that: 84% of 6-month-old infants had a negative mother antibody, positive antibody levels are also very low. After vaccination, the positive rate of antibody reached 86 6%, the immune success rate was 80 7% and the geometric mean titer (GMT) was 1:5 2 8 45. After inoculation, the rates of fever and rash were 16 8% and 25% 2 %. It is feasible to implement the 6-month-old MV priming procedure. Compared with the initial monitoring data of 8-month-old infants in this city, the success rate of MV immunization and low GMT of 6-month-old infants indicated that the presence of infant’s mother antibodies had some interference with the success rate of MV, Relevant factors such as the degree of development of the immune system in low-age infants may be the more dominant factor affecting the immune response. Recommendations: To study the cost-effectiveness of 6-month-old and 8-month-old infants with MV pre-immunization, and if taking a 6-month-old prime, consideration should be given to re-inoculation of 1 dose of MV at the age of one; accelerating the development of a vaccine that is immunogenic and suitable for low A new MV for month-old infants; A closer look at age-related factors.